Ying Dong, MD, PhD

Pharmacokinetics and Safety of RYKINDO® (Risperidone) for Extended-Release Injectable Suspension, a Novel Long-Acting Injectable Risperidone, in Patients With Schizophrenia and/or Schizoaffective Disorder

This randomized, open-label, relative bioavailability study comparatively evaluated the pharmacokinetics and safety of RYKINDO®, a novel long-acting risperidone administered biweekly (Q2W...

Ying Dong , MD, PhD;

10/26/2023

Population Pharmacokinetics for Switching From Oral or Long-Acting Injectable Risperidone to RYKINDO® (Risperidone) for Extended-Release Injectable Suspension, a Novel Long-Acting Injectable, in Patients With Schizophrenia

In adult patients with schizophrenia, switching from RISPERDAL CONSTA® (RC) to RYKINDO® requires administration of the first RYKINDO injection 4-5 weeks after the last RC injection. For p...

Ying Dong , MD, PhD;

10/26/2023